Verona Pharma’s FDA Approval for New COPD Treatment
Company Announcements

Verona Pharma’s FDA Approval for New COPD Treatment

The latest announcement is out from Verona Pharma (VRNA).

Verona Pharma plc has announced FDA approval of Ohtuvayre (ensifentrine) for treating chronic obstructive pulmonary disease (COPD) in adults, marking a significant milestone for the company. This innovative treatment, which uniquely combines bronchodilator and anti-inflammatory effects, promises ease of use through a standard jet nebulizer. Ohtuvayre, set to hit the market in Q3 2024, is expected to be distributed exclusively via accredited specialty pharmacies, making it a noteworthy development for investors tracking pharmaceutical innovations and market entries.

Find detailed analytics on VRNA stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyVerona Pharma management to meet with BTIG
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App